Holen Sie sich die Stockscreener-App
0.671
4.14%
-0.029
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
Critical Analysis: ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Schrödinger (NASDAQ:SDGR) - Defense World
ZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded at Wall Street Zen - Defense World
ZyVersa Therapeutics Stockholders Approve Key Proposals - TipRanks
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
At $0.65 Price, ZyVersa Therapeutics Inc (ZVSA) Is Sitting And Waiting - Stocksregister
ZyVersa Therapeutics Reports Q1 2025 Financial Results - TipRanks
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
ZVSA: ZyVersa Therapeutics' IC 100 Shows Promise in PD Treatment - GuruFocus
ZyVersa’s IC 100 shows promise in Parkinson’s treatment By Investing.com - Investing.com India
ZyVersa Therapeutics highlights publication of data on IC 100 - TipRanks
ZyVersa’s IC 100 shows promise in Parkinson’s treatment - Investing.com Australia
ZyVersa Therapeutics Highlights Published Study Reinforcing - GlobeNewswire
Breakthrough Study Reveals Key to Fighting Parkinson's: ZyVersa's Novel Drug Shows Promise in $13B Market - Stock Titan
ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India
ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire
ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks
ZyVersa progresses with obesity inflammation treatment - Investing.com Australia
ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan
ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com
ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com
Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus
Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq
ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire
Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):